Disease modification and Neuroprotection in neurodegenerative disorders

The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward

(2017) Stéphane Lehericy et al.   MOVEMENT DISORDERS

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials

(2017) Günter U. Höglinger et al.   MOVEMENT DISORDERS

Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research

(2016) Natini Jinawath et al.   Journal of Translational Medicine

Research priorities to reduce the global burden of dementia by 2025

(2016) Hiral Shah et al.   LANCET NEUROLOGY

Failed Alzheimer’s trial does not kill leading theory of disease

(2016) Alison Abbott et al.   NATURE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

(2016) Liang Wang et al.   JAMA Neurology

CSF tau correlates with CJD disease severity and cognitive decline

(2015) O. S. Cohen et al.   ACTA NEUROLOGICA SCANDINAVICA

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study

(2015) Michael Ewers et al.   Alzheimers & Dementia

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

(2015) Clifford R. Jack et al.   BRAIN

Propagation of Pathology through Brain Networks in Neurodegenerative Diseases: From Molecules to Clinical Phenotypes

(2015) Federica Agosta et al.   CNS Neuroscience & Therapeutics

Spreading of pathology in neurodegenerative diseases: a focus on human studies

(2015) Johannes Brettschneider et al.   NATURE REVIEWS NEUROSCIENCE

Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

(2015) Enchi Liu et al.   NEUROLOGY

Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience

(2015) Meghan Mott et al.   Neurotherapeutics

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)

(2015) Heinz Wiendl et al.   Neurotherapeutics

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

(2015) Changqin Liu et al.   PARKINSONISM & RELATED DISORDERS

In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging

(2015) Jorge R. Barrio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease

(2015) Hong Liu-Seifert et al.   PLoS One

Improving and Accelerating Drug Development for Nervous System Disorders

(2014) Diana E. Pankevich et al.   NEURON

Chronic Neuroinflammation in Alzheimer’s Disease: New Perspectives on Animal Models and Promising Candidate Drugs

(2014) Christopher Millington et al.   Biomed Research International

Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

(2013) Maria Landqvist Waldö et al.   BMC Neurology

High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease

(2013) M. Degerman Gunnarsson et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Alzheimer's disease biomarkers: Correspondence between human studies and animal models

(2013) Jonathan J. Sabbagh et al.   NEUROBIOLOGY OF DISEASE

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

(2012) Petra Dunkel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease

(2012) R. Tarawneh et al.   NEUROLOGY

Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease

(2010) Juan Zhou et al.   BRAIN

Bridging the Valley of Death of therapeutics for neurodegeneration

(2010) Steven Finkbeiner   NATURE MEDICINE

ADAGIO trial hints that rasagiline slows disease progression

(2010) Cristina Sampaio et al.   Nature Reviews Neurology

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

(2010) P. Vemuri et al.   NEUROLOGY

Measuring disease progression in frontotemporal lobar degeneration: A clinical and MRI study

(2010) E. Gordon et al.   NEUROLOGY

Defining and labeling disease-modifying treatments for Alzheimer's disease

(2009) Jeffrey L. Cummings   Alzheimers & Dementia

In vivo evidence for the selective subcortical degeneration in Huntington's disease

(2009) Gwenaëlle Douaud et al.   NEUROIMAGE

Neurodegenerative Diseases Target Large-Scale Human Brain Networks

(2009) William W. Seeley et al.   NEURON

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET